UMOJA BIOPHARMA
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer.
UMOJA BIOPHARMA
Industry:
Biopharma Biotechnology Developer Platform Information Technology
Founded:
2019-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.umoja-biopharma.com
Total Employee:
101+
Status:
Active
Total Funding:
263 M USD
Technology used in webpage:
Euro Google Maps IPv6 ReCAPTCHA Google Google Cloud Akamai Hosted
Similar Organizations
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
Current Employees Featured
Andrew Scharenberg Co-founder and CEO @ Umoja Biopharma
Co-founder and CEO
2019-11-01
Philip Low Co-Founder & Director @ Umoja Biopharma
Co-Founder & Director
2019-02-01
Ryan Crisman Co-Founder and Chief Technology Officer @ Umoja Biopharma
Co-Founder and Chief Technology Officer
2019-07-01
Tim Gardner Executive Vice President-Strategy and Business Development @ Umoja Biopharma
Executive Vice President-Strategy and Business Development
2020-01-01
Founder
Investors List
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - Umoja Biopharma
SVB Securities
SVB Securities investment in Series B - Umoja Biopharma
RTW Investments
RTW Investments investment in Series B - Umoja Biopharma
Presight Capital
Presight Capital investment in Series B - Umoja Biopharma
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Umoja Biopharma
Temasek Holdings
Temasek Holdings investment in Series B - Umoja Biopharma
CaaS Capital Management
CaaS Capital Management investment in Series B - Umoja Biopharma
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series A - Umoja Biopharma
MPM Capital
MPM Capital investment in Series A - Umoja Biopharma
DCVC Bio
DCVC Bio investment in Series A - Umoja Biopharma
Official Site Inspections
http://www.umoja-biopharma.com Semrush global rank: 1.3 M Semrush visits lastest month: 20.74 K
- Host name: 64.158.196.104.bc.googleusercontent.com
- IP address: 104.196.158.64
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Umoja Biopharma"
Umoja Biopharma - Crunchbase Company Profile & Funding
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune …See details»
Our Company - Umoja Biopharma
Umoja’s world-class team of scientists, researchers, and drug development experts are united by our shared goal of unlocking the true potential of CAR T cell therapies. Our deep experience, …See details»
Umoja raises $100 million to boost its CAR-T cell gene therapy …
1 hour ago The U.S. biotech company Umoja Biopharma announced this week that it has raised $100 million in a Series C financing round co-led by Double Point Ventures and DCVC Bio, …See details»
Umoja Biopharma - Funding, Financials, Valuation & Investors
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. Search Crunchbase. Start Free Trial . Chrome Extension. ... How …See details»
Umoja Biopharma Announces Oversubscribed $100 Million Series …
2 days ago SEATTLE, WA, January 14, 2025— Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T …See details»
Umoja Biopharma Company Profile - Office Locations, …
Umoja Biopharma has 5 employees across 2 locations and $263 m in total funding,. See insights on Umoja Biopharma including office locations, competitors, revenue, financials, executives, …See details»
Seattle's Umoja Biopharma raises $100 million - Puget Sound …
1 day ago The company's lead treatment is aimed at cancer and autoimmune disease. Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, …See details»
Seattle immunotherapy startup Umoja Biopharma raises $100M
1 day ago Another Seattle-area health startup is raising a big new round of funding. Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company …See details»
Umoja Biopharma - Contacts, Employees, Board Members
Organization. Umoja Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of …See details»
Umoja secures $100M series C to bring more CAR-Ts into the clinic
1 day ago Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic.. Umoja’s only clinical-stage …See details»
Umoja secures $100m to advance CAR-T cell therapy pipeline
1 day ago Umoja Biopharma co-founder and CEO Andrew Scharenberg stated: “We are pleased to announce the closing of our Series C financing with tremendous support from both new and …See details»
Our Pipeline - Umoja Biopharma
1150 Eastlake Ave E, Suite 400 Seattle, WA 98109 info@umoja-biopharma.comSee details»
Umoja Biopharma Company Profile | Management and Employees …
Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. ... SQL International …See details»
Umoja Biopharma - BIO International Convention | BIO
Jun 7, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Umoja …See details»
Umoja Biopharma - PitchBook
Umoja Biopharma General Information Description. Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy …See details»
Umoja Biopharma, Inc. - Drug pipelines, Patents, Clinical trials
SEATTLE, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and …See details»
Umoja Secures $100M For In Vivo CAR-T Therapies
1 day ago Umoja Biopharma has secured $100 million in an oversubscribed Series C funding round. Based in Seattle, Washington, and founded in 2019, Umoja focuses on developing …See details»
Umoja Biopharma Announces Oral Presentation at the American …
SEATTLE, WA, September 30, 2024 — Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and …See details»
Umoja Biopharma - Updates, News, Events, Signals & Triggers
Umoja Biopharma, Inc is focused on advancing immunotherapies for cancer treatment. Their research includes developing xenogenic-free methods for generating hematopoietic …See details»
Umoja Biopharma Announces Oversubscribed $100 Million
1 day ago Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in …See details»